Overview

Effect of Intraperitoneal Ropivacaine on Visceral Pain After Laparoscopic Gastrectomy

Status:
Not yet recruiting

Trial end date:
2024-07-07

Target enrollment:
0

Participant gender:
All

Summary

Visceral pain is obvious and lasts for a long time in patients after laparoscopic gastrectomy.Relieving the visceral pain is of great significance for patients' postoperative emotional experience, functional recovery and reducing the formation of long-term chronic pain. However, there is no clear clinical consensus on relieving visceral pain by now, so effective clinical methods to relieve visceral pain need to be explored urgently. Intraperitoneal spraying local anesthetics is a simple and inexpensive method, which has been proved to be safe and effective in randomized controlled trials and Meta-analysis of various types of surgery.However, its effect in clinical research is still controversial and many studies lack evaluation of postoperative recovery quality, so it has not been widely used in clinical practice. This study aims to explore the effect of intraperitoneal spraying ropivacaine (long-acting amide local anesthetic) on visceral pain after laparoscopic gastrectomy, and to systematically evaluate its effect on the recovery of gastrointestinal function and the inflammatory factors (IL-6, TNF-α) in abdominal drainage fluid.

Phase:

N/A

Accepts Healthy Volunteers?

Details

Lead Sponsor:

SanQing Jin

Treatments:

Ropivacaine

Criteria

Inclusion Criteria:

1. Age 18-65 years old

2. The American Society of Anesthesiologists(ASA) grade is I or II, and the heart
function grade is 1-2;

3. Elective laparoscopic gastrectomy under general anesthesia

Exclusion Criteria:

1. Patients have severe heart, lung, liver, and kidney diseases (heart function grade>3 /
respiratory failure / liver failure / renal failure)

2. BMI<18kg/m2 or >30kg/m2

3. Patients with chronic pain other than stomach pain and taking analgesics for a long
time

4. Patients with history of allergy to local anesthetics

5. Patients with high risk of reflux and aspiration such as digestive obstruction

6. Patients who refuse to participate or don't sign or refuse to sign the informed
consent form

7. Patients who are unable to communicate effectively

8. Patients participate in other clinical trials